Despite the FDA’s ban, copycat versions of Eli Lilly’s Zepbound and Mounjaro remain available online. Websites like Amble, EllieMD, Willow, and Mochi Health continue to advertise tirzepatide, the active ingredient in these drugs. Mochi Health, utilizing a network of about 500 providers, insists on offering personalized versions of the medications. Some pharmacies, like Ivim, have ceased accepting new patients, while others, such as Mochi Health’s four partner pharmacies, plan to continue operations. The FDA allowed smaller pharmacies until early March and larger ones until this week to stop compounding tirzepatide. The agency considers a product an essential copy if its dosage is within 10% of the commercial drug or if it combines multiple commercial drugs. Meanwhile, Town & Country Compounding Pharmacy in Ramsey, New Jersey, stopped compounding tirzepatide earlier this month, affecting 300 to 400 patients who were paying about $200 monthly. The FDA’s enforcement of the ban and potential legal actions by Eli Lilly remain uncertain. Additionally, mass compounding of semaglutide, found in Novo Nordisk’s Ozempic and Wegovy, must cease by the end of May.
Source: www.cnbc.com















